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Abstract
Objectives: Localization of ectopic ACTH‐secreting tumours causing Cushing 
syndrome (ECS) is essential for clinical management, yet often difficult. [68Ga]‐
DOTATATE PET/CT ([68Ga]‐DOTA‐(Tyr3)‐octreotate)] is an FDA‐approved high‐reso‐
lution diagnostic tool for imaging neuroendocrine tumours. Data on the clinical utility 
of [68Ga]‐DOTATATE in patients with ECS, however, are scarce. The objectives of this 
study were to determine the efficacy for ECS localization and the clinical benefit of 
[68Ga]‐DOTATATE imaging.
Method: We conducted a retrospective review of all cases with ECS evaluated with 
[68Ga]‐DOTATATE from November 2016 through October 2018 at three referral 
centres. The clinical benefit of [68Ga]‐DOTATATE was based on detection of new 
tumours and resultant changes in management.
Results: Over the study period, 28 patients with ECS underwent [68Ga]‐DOTATATE: 
17 for identification of the primary tumour and 11 during follow‐up. [68Ga]‐DOTATATE 
identified the suspected primary ECS in 11/17 patients (65%). Of these, nine patients 
underwent surgery: eight with confirmed ECS (5 bronchial, 1 thymic, 1 pancreatic 
and 1 metastatic neuroendocrine tumour of unknown primary origin) and one patient 
with a false‐positive scan (adrenal gland). Of the 11 patients with ECS who under‐
went [68Ga]‐DOTATATE evaluation during follow‐up, the study led to changes in clini‐
cal management in 7/11 (64%) patients.
Conclusions: [68Ga]‐DOTATATE is sensitive in detecting primary and metastatic ECS, 
often identifies occult tumours after conventional imaging, and impacts clinical care 
in the majority of patients.
K E Y W O R D S
[68Ga]‐DOTATATE PET, CT, Cushing syndrome, ectopic ACTH secretion, somatostatin 
receptor, tumour localization
1  | INTRODUC TION
Ectopic ACTH‐secreting tumours often lead to fulminant 
Cushing syndrome (ECS) and are associated with higher mortality 
compared to other causes of cortisol excess.1 Prompt identifi‐
cation and treatment of ECS are imperative for optimal clinical 
outcomes. Surgical cure, however, is achieved in less than half 
of patients with ECS, partly due to unresectable metastases 
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and also because many such tumours are small and difficult to 
localize.2‐6
Cross‐sectional anatomic imaging is commonly used as first‐line 
radiographic investigation for identification of ECS, but its sensitiv‐
ity for ECS detection is suboptimal, ranging from 52% to 66%.7,8 In 
a systematic review, various nuclear medicine functional imaging 
techniques identified 79% of ECS not detected by initial conventional 
anatomic imaging.8 Scintigraphy or single‐photon emission computed 
tomography (SPECT) with [111In]‐pentetreotide, a somatostatin recep‐
tor (SSTR) ligand (SRL), and [131I]‐ or [123I]‐metaiodobenzylguanidine 
(MIBG), a catecholamine analog, are commonly used for NET detec‐
tion, but these studies require prolonged time (imaging at 24‐48 hours 
after radiotracer injection) and have relatively limited sensitivity 
for disease detection.9 Positron emission tomography (PET) offers 
significantly improved imaging quality and shorter protocols 10,11 
using a variety of tracers, including [18F]‐fluorodeoxyglucose (FDG), 
[18F]‐dihydroxyphenylalanine (DOPA) and [68Ga]‐DOTATATE (DOTA‐
(Tyr3)‐octreotate).7,12,13 For SRL imaging, [68Ga]‐DOTATATE PET/CT 
has proven to be more sensitive than [111In]‐pentetreotide SPECT in 
detecting various NETs.14‐18 The advantages of [68Ga]‐DOTATATE in 
patients with ECS, however, have only been described in isolated case 
reports or small case series.18,19 Here we retrospectively studied the 
use of [68Ga]‐DOTATATE in localizing ECS and the resultant impact on 
clinical management beyond conventional imaging.
2  | PATIENTS AND METHODS
We conducted a retrospective study of all cases with ECS evaluated 
with [68Ga]‐DOTATATE imaging in three tertiary referral centres 
 
University of 
Michigan 
N = 17
Mayo Clinic 
Rochester 
N = 6
MD Anderson 
Cancer Center 
N = 5
Total 
N = 28
Age (years) 49 [33‐49] 50 [39‐63] 51 [43‐64] 50 [38‐64]
Sex (F/M) 15/2 4/2 3/2 22/6
Clinical diagnosis of CS
Moon face 12 4 5 21 (75%)
Dorsocervical fat pad 8 3 3 14 (50%)
Supraclavicular fat pad 8 5 2 15 (54%)
Purplish striae 9 3 0 12 (43%)
Facial plethora 11 4 1 16 (57%)
Central obesity 11 4 4 19 (68%)
Proximal muscle weakness 16 5 5 26 (93%)
Hypokalemia 13 4 3 20 (71%)
Hyperglycaemia 12 5 4 21 (75%)
Hypertension 14 5 4 23 (82%)
Biochemical diagnosis of CS
Basal cortisol (µg/dL) 61 [41‐78] 30 [19‐44] 64 [24‐103] 56 [28‐70]
Basal ACTH (pg/mL) 160 [101‐294] 112 [84‐202] 123 [92‐167] 127 [89‐245]
Urine free cortisol 
(µg/24 h)
1229 [315‐3234] 289 [167‐3342] 441 [404‐3151] 730 [225‐3456]
ECS diagnosis
Bronchial NET 5 2 1 8
Pancreatic NET 2 2 1 5
MTC 2 0 0 2
Ileal NET 1 0 0 1
Thymic NET 1 0 0 1
Non‐small‐cell lung cancer 1 0 0 1
NET‐unknown primarya 5 2 3 10
Note: Age and biochemical data were expressed as medians [interquartile range].
Abbreviations: ACTH, adrenocorticotropic hormone; CS, Cushing syndrome; ECS, ectopic ACTH‐secreting 
tumour causing Cushing syndrome; F, female; MTC, medullary thyroid carcinoma; NET, neuroendocrine 
tumour.
aNET of unknown primary origin included seven occult NETs (including one false‐positive lesion) and 3 
metastatic NETs with unclear primary site. 
TA B L E  1   Characteristics of study 
participants
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(University of Michigan, Mayo Clinic, Rochester, and The University 
of Texas MD Anderson Cancer Center) since FDA approval 
(November 2016), through October 2018. Patient demographics, 
clinical evaluation, imaging modalities, laboratory, histopathological 
results and treatment data were reviewed. The study was conducted 
with approval and waiver of informed consent from the Institutional 
Review Board at the University of Michigan, Mayo Clinic (Rochester) 
and MD Anderson Cancer Center.
The diagnosis of Cushing syndrome was confirmed by clinical and 
hormonal evaluation, in accordance with the Endocrine Society practice 
guidelines (Table 1).9 Ectopic ACTH syndrome was defined by hormonal 
assessment compatible with ACTH‐dependent Cushing syndrome, in 
conjunction with the absence of central gradient during bilateral inferior 
petrosal sinus sampling or known ECS.3,4 All cross‐sectional imaging, 
[111In]‐pentetreotide scintigraphy and SPECT, [68Ga]‐DOTATATE and 
[18F]‐FDG PET/CT images were reviewed by experienced radiologists 
and nuclear medicine physicians in each institution.
The clinical impact of [68Ga]‐DOTATATE was defined as the de‐
tection of primary ECS or new metastatic foci, along with conse‐
quent changes in clinical management.
3  | RESULTS
Over the study period, 28 patients (age 18‐77 years, median 50, 
78.6% females) with ectopic ACTH syndrome underwent [68Ga]‐
DOTATATE scan, including 17 patients to localize the primary ECS 
(Table 1). Of these, the primary tumour was occult after previ‐
ous imaging in 15 patients (cross‐sectional imaging in all patients, 
[18F]‐FDG PET/CT scan in four patients and [111In]‐pentetreotide 
in three other patients), and in two patients, [68Ga]‐DOTATATE 
scan was the first localizing imaging study used (Figure 1). [68Ga]‐
DOTATATE scan identified an ECS in 11/17 (65%) patients, of 
which seven were solitary and 4 metastatic. The diagnosis was 
confirmed by pathology in 8/11 patients: 5 bronchial NET, 1 thymic 
NET, 1 pancreatic NET and 1 metastatic NET of unknown pri‐
mary origin. Surgical cure was achieved in seven of these patients 
(Figures 2,3), while 1 remaining patient had widely metastatic dis‐
ease. In this latter patient who was not cured, [68Ga]‐DOTATATE 
identified bronchial and bone lesions but failed to identify liver 
metastases, which were apparent on MRI and confirmed by bi‐
opsy, illustrating false‐negative metastases (Figure 4). In another 
patient with occult ECS, [68Ga]‐DOTATATE demonstrated a nodu‐
lar focus of uptake in the left adrenal gland (Figure 3). Clinical 
cure, however, was not achieved after left adrenalectomy, and pa‐
thology showed adrenocortical hyperplasia. This case illustrates 
a false‐positive scan, which caused a delay in contralateral adre‐
nalectomy and cure of the hypercortisolaemia. Of the remaining 
two patients, one was lost to follow‐up, and the second is awaiting 
surgery. Of the seven patients in whom the ECS source remained 
occult after [68Ga]‐DOTATATE PET/CT scan, three patients un‐
derwent bilateral adrenalectomy, two were treated with mifepris‐
tone, and two were treated with ketoconazole for management of 
hypercortisolaemia.
[68Ga]‐DOTATATE was performed to assess disease burden or 
recurrence in 11 patients with known ECS (Figure 1): 4 pancreatic 
NETs; 2 unknown primary neuroendocrine carcinomas; 2 med‐
ullary thyroid cancers (MTC); 1 ileal NET; 1 bronchial NET; and 1 
non‐small‐cell lung cancer (NSCLC). [68Ga]‐DOTATATE identified 9 
new metastatic foci and 3 recurrent tumours: 5 solitary bone lesions, 
3 pancreatic lesions and 1 intra‐abdominal lymph node. Of the 11 
patients with known ECS, [68Ga]‐DOTATATE evaluation during fol‐
low‐up period led to changes in clinical management in 7 cases: in 
three patients with widely metastatic cancer previously treated with 
chemotherapy (2 MTC and 1 pancreatic NET), [68Ga]‐DOTATATE up‐
take in numerous metastatic foci (Figure 5) led to treatment with 
F I G U R E  1   Patients with ECS 
evaluated at University of Michigan, Mayo 
Clinic Rochester and The University of 
Texas MD Anderson Cancer Center who 
underwent [68Ga]‐DOTATATE PET/CT 
between November 2016 and October 
2018. The dimensions of ECS detected by 
[68Ga]‐DOTATATE PET/CT imaging ranged 
from 0.8 to 2.8 cm for primary tumour 
localization or 0.4‐1.8 cm for newly found 
metastases. Pathology revealed poorly 
differentiated NET in 2 patients and 
well‐differentiated NET in 6. ECS, ectopic 
ACTH‐secreting tumour causing Cushing 
syndrome; NET, neuroendocrine tumour
Yes
N = 7
Surgical intervention
N = 9
Pathologically proven NETs N = 8
False positive lesion N = 1 
Pending surgery
N = 2
Change in management of ECS patients 18/28 = 64% 
[68Ga]-DOTATATE PET/CT in ECS
Nov 2016-Oct 2018
N = 28
For localization of primary ECS
N = 17
For to assess disease burden or recurrence 
N = 11
ECS identified
N = 11
ECS not found 
N = 6
No
N = 4
Change in 
management?
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[177Lu]‐ or [90Y]‐labelled peptide‐receptor radionuclide therapy 
(PRRT); in two patients with prior surgical removal of primary ECS 
(one bronchial and one pancreatic NET), [68Ga]‐DOTATATE identi‐
fied single recurrent left upper lung and pancreatic bed lesions, re‐
spectively, which were subsequently removed; in one patient with 
NET of unknown primary origin, [68Ga]‐DOTATATE demonstrated 
new focal bone lesions, which led to treatment with everolimus; and 
in the last patient with pancreatic NET, 2 metastatic foci were found 
in the pancreatic tail, which prompted treatment with a somatostatin 
analogue. In the remaining 4 cases (1 pancreatic NET, 1 ileal NET, 1 
NSCLC and 1 NET of unclear primary origin; all metastatic), [68Ga]‐
DOTATATE findings were concordant with conventional imaging.
The dimensions of newly detected lesions with [68Ga]‐DOTATATE 
PET/CT imaging, either primary or metastatic, ranged from 0.4 to 
F I G U R E  2   [68Ga]‐DOTATATE PET/CT demonstrated focal uptake in the upper lobe of the left lung (A, B, C), two foci of uptake in the left 
hilar region (A), and a left thoracic inlet lymph node (LN) (D) [Colour figure can be viewed at wileyonlinelibrary.com]
(A) (B) (C)
(D)
F I G U R E  3   [68Ga]‐DOTATATE PET/CT demonstrated uptake in the thymus (A, C) and mediastinal lymph node (A, B, C). Pathology revealed 
high‐grade thymic NET with mediastinal lymph node metastasis. [68Ga]‐DOTATATE PET/CT revealed focal uptake in the left adrenal gland (D, E). 
CT abdomen showed left adrenal thickening (F). Left adrenalectomy was performed, but pathology demonstrated adrenal cortex hyperplasia but 
no malignant tumour, and hypercortisolism did not resolve. NET, neuroendocrine tumour [Colour figure can be viewed at wileyonlinelibrary.com]
(A)
(D) (E) (F)
(B) (C)
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2.8 cm. Of the eight patients with primary ECS confirmed by pathol‐
ogy, six were classified as well‐differentiated NET (5 bronchial and 1 
pancreatic) and two as poorly differentiated NET (1 thymic and 1 of 
unknown primary origin). The majority of primary tumours identified 
by [68Ga]‐DOTATATE PET/CT were not recognized on cross‐sectional 
imaging, especially tumours <1 cm. In two patients, [68Ga]‐DOTATATE 
PET/CT detected tumours in the right middle lung fields that were 
misidentified as vascular in origin. In retrospect, however, an anatomic 
correlate to all DOTATATE‐avid tumours except bone metastases 
could be identified on cross‐sectional imaging (Figures 2‐5).
4  | DISCUSSION
In this retrospective series of 28 patients with ectopic ACTH pro‐
duction leading to Cushing syndrome, [68Ga]‐DOTATATE localized 
F I G U R E  4   [68Ga]‐DOTATATE PET/CT demonstrated uptake in the right hilar area (A, B), 8th thoracic vertebra (C) and right iliac bone (D) but 
failed to identify three liver metastases, apparent on MRI, and confirmed by biopsy. Right liver lobe metastases (E, F) and left liver lobe metastasis 
(G) in a patient with NET of unclear primary origin. NET, neuroendocrine tumour [Colour figure can be viewed at wileyonlinelibrary.com]
(A)
(E) (F) (G)
(B) (C) (D)
F I G U R E  5   [68Ga]‐DOTATATE PET/CT demonstrated new bone metastatic lesions in the right humerus (B), 3rd thoracic vertebra (C), 4th 
lumbar vertebra (D) and right femur (E) in a patient with medullary thyroid cancer with liver and lymph node metastasis (A) [Colour figure can 
be viewed at wileyonlinelibrary.com]
(A) (B) (C)
(D) (E)
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the primary tumour and/or metastases in the majority of study pa‐
tients. [68Ga]‐DOTATATE is a recently approved advanced molecular 
imaging probe with high affinity for SSTR type 2 (0.2 ± 0.04 nmol/L, 
as compared to 22 ± 3.6 nmol/L for [111In]‐pentetreotide),20 which, 
when coupled with the advanced spatial resolution of PET/CT imag‐
ing systems, can result in successful detection and accurate localiza‐
tion of small tumours characterized by SSTR expression. A review of 
the literature found that [68Ga]‐DOTATATE is highly sensitive (81.8%) 
in localization of ECS; however, only 23 of 231 patients assimilated 
from these studies received [68Ga]‐DOTATATE imaging.8 Papadakis 
previously published a case of a ectopic Cushing and CRH co‐secret‐
ing tumour, identified by [68Ga]‐DOTATATE PET/CT.21 ECS is often 
highly functional and associated with a fulminant clinical course and 
high mortality. Thus, ECS localization is critical for managing this ag‐
gressive form of Cushing syndrome. Despite extensive conventional 
cross‐sectional and functional imaging, up to 19% of ECS remain oc‐
cult.2‐4 In our study, [68Ga]‐DOTATATE identified the primary ECS 
in 11/17 (65%) of previously occult tumours. The somewhat lower 
overall accuracy of [68Ga]‐DOTATATE PET/CT in our series might re‐
flect a selection bias for difficult cases at our referral centres, with a 
high prevalence of occult ECS.
Most of these ECS were located in the thorax, and some were 
smaller than 1 cm, which is near the limit of detection for other 
imaging modalities. Furthermore, [68Ga]‐DOTATATE detected not 
only well‐differentiated NET, but also a poorly differentiated ECS, 
which are composed of highly proliferative cells with low SSTR ex‐
pression and high metabolic activity, as evidenced by [18F]‐FDG 
PET/CT.11,22 Hypercortisolaemia can lower SSTR expression in 
EAS23 and result in false‐negative scintigraphy, which can be re‐
versed with glucocorticoid antagonist therapy.24 In our series of 
10 patients with previously occult tumours that were located with 
[68Ga]‐DOTATATE scans, three and one were treated with mifepris‐
tone and ketoconazole, respectively. Similarly, of the seven patients 
with tumours that were not located with [68Ga]‐DOTATATE scans, 
three each were treated with mifepristone or ketoconazole prior 
to the scanning. Thus, six of seven false‐negative scans failed to 
identify the source of ACTH despite concomitant treatment of hy‐
percortisolaemia. [68Ga]‐DOTATATE imaging was performed only 
once in all patients, which precludes any conclusions about lon‐
gitudinal changes or comparisons with and without treatment of 
hypercortisolaemia.
Of previously identified ECS, [68Ga]‐DOTATATE impacted clinical 
management in 7/11 (64%) of patients. [68Ga]‐DOTATATE allowed 
cure of recurrent disease in two patients and identified three other 
patients as candidates for PRRT with [177Lu]‐ or [90Y]‐labelled soma‐
tostatin analogs. 10,11,25
Physiologic uptake of [68Ga]‐DOTATATE in several locations such 
as liver, spleen, adrenal glands, thyroid, pancreas and kidneys can 
confound image interpretation.26,27 A previous systematic review 
described one case of lung NET with a false‐positive focus of up‐
take in the adrenal gland.28 Similarly, in our study, an ACTH‐secret‐
ing pheochromocytoma was suspected in one patient with occult 
tumour who had atypical peripheral [68Ga]‐DOTATATE uptake in 
the left adrenal gland and normal plasma metanephrines (Figure 3). 
Cushing syndrome was not resolved after left adrenalectomy, and 
histopathology showed adrenal cortical hyperplasia. Conversely, in 
another patient with metastatic NET of unknown primary origin, 
[68Ga]‐DOTATATE‐avid osseous and pulmonary metastatic lesions 
were found, but biopsy‐proven liver metastases could not be de‐
tected (Figure 4), perhaps due to the high background activity of 
liver and/or poor SSTR expression in certain clonal cell populations. 
One review of [68Ga]‐DOTATATE imaging for detecting ECS reported 
17.4% false‐negative studies.8
Our study demonstrates the high sensitivity of [68Ga]‐DOTATATE 
in the localization of ECS, for both occult primary tumours and met‐
astatic lesions. Importantly, the use of [68Ga]‐DOTATATE impacted 
clinical management in 64% patients with ECS overall. High cost and 
limited availability of PET/CT imaging, however, might preclude the 
widespread use of [68Ga]‐DOTATATE for ECS imaging, and experi‐
ence with these scans, which were FDA‐approved for clinical use in 
the USA to localize relatively rare tumors in June 2016, is somewhat 
limited compared to other imaging studies. Limitations of our study 
include the small number of patients and the retrospective study de‐
sign. In addition, the choice of imaging modalities, the management 
of hypercortisolaemia and the long‐term plan of management were 
not prespecified and were subject to many subjective and circum‐
stantial influences. Nonetheless, combining the experience of three 
large referral centres, our study gathers the largest number of ECS 
imaged with [68Ga]‐DOTATATE to date and provides a benchmark for 
the utility of this diagnostic modality for this rare but highly morbid 
condition. Further prospective investigations are needed to charac‐
terize the benefits and pitfalls of [68Ga]‐DOTATATE in diagnosis and 
follow‐up of patients with ECS.
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